[PDF][PDF] 氯喹引起的致死性心脏不良事件分析: 基于WHO 个案病例安全报告全球数据库相关数据的研究
张青霞， 白向荣， 岳群英 - 药物不良反应杂志, 2020 - cadrj.com
目的分析新型冠状病毒肺炎抗病毒治疗推荐药物氯喹引起致死心脏不良事件的临床特征,
为临床安全用药提供参考. 方法检索世界卫生组织个案病例安全报告全球数据库(VigiBase) …
为临床安全用药提供参考. 方法检索世界卫生组织个案病例安全报告全球数据库(VigiBase) …
Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports
Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's
List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and …
List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and …
[HTML][HTML] Serious cardiovascular adverse events associated with hydroxychloroquine/chloroquine alone or with azithromycin in patients with COVID-19: a …
Y Zhao, J Zhang, K Zheng, S Thai… - Drugs-Real World …, 2022 - Springer
Background The use of hydroxychloroquine or chloroquine (HCQ/CQ) as monotherapy or
combined with azithromycin for the treatment of coronavirus disease 2019 (COVID-19) may …
combined with azithromycin for the treatment of coronavirus disease 2019 (COVID-19) may …
[HTML][HTML] Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports
Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's
List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and …
List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and …
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports
Aim There is a clinical need for safety data regarding hydroxychloroquine (HCQ) and
chloroquine (CQ) during the coronavirus (COVID‐19) pandemic. We analysed real‐world …
chloroquine (CQ) during the coronavirus (COVID‐19) pandemic. We analysed real‐world …
[PDF][PDF] 氯喹严重不良反应的临床表现及处理
张波， 左玮， 胡扬， 闫雪莲， 杨阳， 梅丹， 刘鑫… - 药物不良反应杂志, 2020 - cadrj.com
国家卫生健康委员会和国家中医药管理局发布的《 新型冠状病毒肺炎诊疗方案(试行第六版)》
指出, 可试用磷酸氯喹进行抗病毒治疗. 氯喹既往用于疟疾, 肠外阿米巴病和类风湿关节炎等疾病 …
指出, 可试用磷酸氯喹进行抗病毒治疗. 氯喹既往用于疟疾, 肠外阿米巴病和类风湿关节炎等疾病 …
[HTML][HTML] A pharmacovigilance study of hydroxychloroquine cardiac safety profile: potential implication in COVID-19 mitigation
In light of the favorable outcomes of few small, non-randomized clinical studies, the Food
and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to …
and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to …
Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults
PS Nishtala, S Gill, T Chyou - Pharmacoepidemiology and drug …, 2020 - Wiley Online Library
Purpose The purpose of this study is to analyze the US FDA Adverse Event Reporting
System (FAERS) to identify adverse cardiac events of hydroxychloroquine in older adults …
System (FAERS) to identify adverse cardiac events of hydroxychloroquine in older adults …